Study With GW274150 In Patients With Mild Asthma

Single Centre Allergen Challenge Study of GW274150 in Mild Asthmatic Subjects

This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response. This will be compared with the response after treatment with a dummy (placebo) and a tablet treatment for asthma called Singulair (montelukast). Subjects in the study will receive all 3 treatments in a random order. The study is double-blind so subjects will not know which treatment they are taking at any given time.

Inclusion criteria:

• Mild asthma: taking reliever medication (e.g. salbutamol) only.
• Screening involves measuring responses to the lung challenge agents: allergen, AMP, and methacholine. Only those with specific types of response to these will be eligible for the study.

Exclusion criteria:

• Recent steroid treatment.
• Significant illnesses or diseases other than asthma.